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INTRODUCTION
Genomic DNA hypomethylation has been observed in the
peripheral blood mononuclear cells of leukemia patients and
in tumor cells of patients with B-cell lymphoproliferative dis-
eases (1). DNA methylation may affect karyotypic stability,
may influence euchromatin-heterochromatin interactions, and
has been correlated with disease progression (2). On the other
hand, promoters of some tumor suppressive genes are often
hypermethylated (3-6). For example, some patients with lym-
phomas do not express tumor suppressor genes because the
promoters of these genes are methylated.
Leukemia is a hematological cancer of the bone marrow and
lymphatic system. In leukemia, bone marrow produces a large
number of abnormal white blood cells, which overwhelm the
other types of blood cells, including red blood cells and pla-
telets, thus impairing the production of normal white blood
cells. In clinical classification, leukemia can be classified as
acute myeloid leukemia (AML) and chronic myeloid leukemia
(CML). AML is a serious and lethal disease that affects adults.
CML is a clonal disease of stem cell origin that is character-
ized by the presence of the Philadelphia chromosome (Ph+),
which has been named t(9,22)(q34:q11). Its fusion gene prod-
uct, Bcr-Abl, is a constitutively active tyrosine kinase. These
facts suggest that somewhat different mechanisms may be in-
volved in AML and CML. Nevertheless, the differential fac-
tors through which they produce a different type of leukemia
are not yet completely understood.
In hematopoietic malignancies, hypermethylation of sev-
eral genes including E-cadherin, DAP kinase, estrogen recep-
tor (ER) alpha, and p15INK4B are associated with gene inacti-
vation (7-10). Genes, such as DAB2IP, DLC-1, H-cadherin,
ID4, Integrin α 4, RUNX3, SFRP1, and SHP1, has been identi-
fied as being implicated in aberrant DNA methylation dur-
ing development of human malignancy (11-18). In order to
gain insight into the differential epigenetic alterations in leu-
kemia, we investigated the methylation statuses at selected
locus of these genes in AML and CML patients using a methy-
lation-specific polymerase chain reaction (MSP).
MATERIALS AND METHODS
Sample collection
Diagnostic bone marrow samples were obtained from 23
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Differential Methylation Pattern of ID4, SFRP1, and SHP1 between
Acute Myeloid Leukemia and Chronic Myeloid Leukemia
To gain insight into the differential mechanism of gene promoter hypermethylation
in acute and chronic leukemia, we identified the methylation status on one part of
5′ CpG rich region of 8 genes, DAB2IP, DLC-1, H-cadherin, ID4, Integrin α 4, RUNX3,
SFRP1, and SHP1 in bone marrows from acute myeloid leukemia (AML) and chronic
myeloid leukemia (CML) patients. Also, we compared the methylation status of genes
in AML and CML using methylation-specific PCR (MSP). The frequencies of DNA
methylation of ID4, SFRP1, and SHP1 were higher in AML patients compared to
those in CML patients. In contrast, no statistical difference between AML and CML
was detected for other genes such as DLC-1, DAB2IP, H-cadherin, Integrin α 4, and
RUNX3. Taken together, these results suggest that these methylation-controlled
genes may have different roles in AML and CML, and thus, may act as a biological
marker of AML.
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Accepted : 17 July 2008patients with AML and 21 patients with CML. The samples
were gathered by the Division of Hematology/Oncology (De-
partment of Internal Medicine, Korea University Medical
Center, Seoul, Republic of Korea) and analyzed by patholo-
gist. Institutional review board approval and informed con-
sent were obtained (KUMC-IRB-2006011-P-1, KUMC-
IRB-2006012-P-2). Of the AML patients, 17 males and 6
females were included, with ages ranging from 26 to 78 yr,
at a median age of 45.61 (SD, 15.56) yr. Of the CML patients,
11 males and 10 females were included, with ages ranging
from 18 to 75 yr (mean±SD, 49.91±16.53). As controls,
22 normal peripheral bloods were obtained from healthy vol-
unteers (11 males and 10 females) ranging from 20 to 78 yr
of age (mean±SD, 45.36±20.64).
Sodium bisulfite treatment and MSP
Chemical modification was performed as described previ-
ously, with minor modifications (19). In brief, 1 μ g of genom-
ic DNA was denatured by incubation with 0.2 M NaOH for
10 min at 37℃, followed by the addition of 550 μ L of 3 M
sodium bisulfite (pH 5.0) (Sigma, St. Louis, MO, U.S.A.) and
10 mM hydroquinone (Sigma), which was brought to a final
volume of 600 μ L. The mixtures were incubated at 55℃ for
16 hr, and the modified DNA was then desalted with the Wiz-
ard Clean-Up system (Promega Corp., Madison, WI, U.S.A.).
We performed polymerase chain reaction (PCR) using spe-
cific PCR primers capable of distinguishing between methy-
lated and unmethylated DNA sequences. The primers for the
unmethylated and methylated DNA sequences, PCR prod-
uct size, and annealing temperature are shown in Table 1. The
MSP primer sets were selected at the 5′ -CpG island regions
of genes using the MethPrimer software (www.urogene.org).
The PCR conditions were as follows: initial denaturation and
hot start at 95℃ for 5 min, and cycles consisting of 30 sec
at 95℃, 30 sec at the annealing temperature, and 30 sec at
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PCR, polymerase chain reaction; temp., temperature; UF, unmethylated forward-sequence; UR, unmethylated reverse-sequence; MF, methylated for-
ward-sequence; MR, methylated reverse-sequence.
Annealing PCR Product
Reference/
Primers 5′ 3′ temp. (℃) cycles size (bp)
Gene bank
accession no.
DAB2IP UF GGT GTT GTT AAG GTA ATA GT 52 37 181 NT 008470
UR CCT TAC TAA ACA ACC ACA CA
MF GGC GTC GTT AAG GTA ATA GC 64 32 176
MR CTA AAC GAC CGC GCG ACC GA
DLC-1 UF AAA CCC AAC AAA AAA ACC CAA CTA ACA 55 37 172 (12)
UR TTT TTT AAA GAT TGA AAT GAG GGA GTG
MF CCC AAC GAA AAA ACC CGA CTA ACG 55 37 172
MR TTT AAA GAT CGA AAC GAG GGA GCG
H-Cadherin UF GTG GGG TTT GTT TTT TGT GAG GT 56 38 260 NT 010498
UR CCA ACT AAA AAC ACC CAA CAA CA
MF GCG GGG TTC GTT TTT CGC GAG 64 38 260
MR CCG ACT AAA AAC GCC CGA CGA
ID4 UF GAG GTA AAG GGA GTG GAG TTG GTT 62 35 155 NT 007592
UR CAA CCC AAC AAC ACC TTA CAA CCC
MF GAG GTA AAG GGA GCG GAG TCG GTC 65 32 155
MR CAA CCC GAC GAC GCC TTA CGA CCC
Integrin α 4 UF GTT TAG AGT TGT TTT GTG TTT TGT G 59 39 193 (15)
UR AAA ACT TCA AAT ACT CAC ACT ACT
MF TAG AGT TGT TTC GCG TTT TGC G 59 37 186
MR CTT CGA ATA CTC GCG CTA CTT
RUNX3 UF GTG GGT GGT TGT TGG GTT AGT GAG 59 37 130 NT 004610
UR CAC CTC CTC AAC CAC CAC TAC CAC
MF GTC GTC GGG TTA GCG AGG TTT CGT 59 37 130
MR CGA CCG ACG CGA ACG CCT CCT C
SHP1 UF GGG TTT GGT TGT AGG AGT TTT GTG TA 62 35 171 (17)
UR CTC AAC CTA CAA TCA AAA ACA ACA CAA
MF TGT AGT TTT CGG AGT TAG TGT CGC GC 68 35 126
MR CCT ACG ATC GAA AAC GAC GCG AAC G
SFRP1 UF GTG TTT GGT ATT CAG TAG GAT TTA TTT G 59 37 193 NT 009759
UR CAA ACC CAA ACA ATC CCA CAA C
MF GCG TTG GGT ATT TAG TAG GAT TTA TTC G 59 37 130
MR CGA ACC CAA CAG ATC CCA CGA
Table 1. Sequences of primers and PCR conditions72℃. In addition, SCK, a human cholangiocarcinoma cell
line, was used as positive control for Integrin α 4 gene (20).
Statistical analysis
MSP results were analyzed as a dichotomous variable based
on the presence or absence of gene methylation. The MSP
results of tumor and normal samples were compared and ana-
lyzed with the Pearson chi-square test (Version 12; SPSS Inc.,
Chicago, IL, U.S.A.). Statistical significance was defined as a
Pvalue of <0.05.
RESULTS
The multiple genes were found to be methylated in bone
marrow from patients with AML or CML. Specifically, the
frequencies of promoter hypermethylation at selected locus in
the 23 AML samples were: 78.3% (18/23) for SHP1, 65.2%
(15/23) for ID4 and SFRP1, 26.1% (6/23) for H-cadherin, 8.7%
(2/23) for DLC-1, and 4.3% (1/23) for DAB2IP and RUNX3.
The frequencies of DNA hypermethylation at selected locus
in the 21 CML samples were: 28.6% (6/21) for SHP1, 19.0%
(4/21) for H-Cadherin, 14.3% (3/21) for ID4, 9.5% for (2/21)
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Fig. 1. PCR product images of the DAB2IP, DLC-1, H-Cadherin, ID4, Integrin α 4, RUNX3, SFRP1, and SHP1 genes in normal peripheral
bloods, acute myeloid leukemias, and chronic myeloid leukemias.
N, normal peripheral blood; A, acute myeloid leukemia; C, chronic myeloid leukemias; U, amplified products used as primers for the unmethy-
lated sequence in normal peripheral blood; M, amplified products used as primers for the methylated sequence.for SFRP1, and 0% (0/21) for DAB2IP, DLC-1, Integrin α 4,
and RUNX3 (Fig. 1). However, promoter hypermethylation
of the 22 normal peripheral bloods was observed less frequent-
ly (Table 2).
There was a statistically significant difference between nor-
mal peripheral bloods and AML with respect to the frequen-
cies of methylation of ID4, SFRP1, and SHP1 (Pearson chi-
square test; P<0.0001, P<0.0001, and P<0.0001, respec-
tively) and between normal peripheral bloods and CML with
respect to the frequencies of SHP1 methylation (Pearson chi-
square test; P=0.007). Furthermore, there was a statistically
significant difference between the DNA methylation frequen-
cies of AML patients and CML patients. The frequencies of
DNA methylation of ID4, SFRP1, and SHP1 were higher
in AML compared to those in CML (P=0.001, P<0.0001,
and P=0.001, respectively) (Table 2). In contrast, no statis-
tical differences between AML and CML were detected in
other genes such as DLC-1, DAB2IP, H-cadherin, Integrin α 4,
and RUNX3. Promoter methylation results at selected locus
of eight genes with MSP method were shown in Fig. 1. These
results suggest that there may be differential epigenetic modi-
fication between AML and CML.
DISCUSSION
Differential epigenetic alteration is observed in AML and
CML patients. The results of the present study demonstrate
the substantially increased frequency of promoter hyperme-
thylation in ID4, SFRP1, and SHP1 genes in AML compared
to CML.
Leukemia, a heterogeneous group of hematopoietic malig-
nancies that occur worldwide, includes acute and chronic my-
eloid leukemia. Despite many important advances in under-
standing the different biological and cytogenetic aspects of
acute and chronic leukemia, a number of questions remained
unanswered. It is understood that some kinds of leukemia
present specific cytogenetic alterations (21). Different types
of leukemia usually have specific epigenetic modifications that
cause the activation of oncogenes and, in particular, the for-
mation of abnormal fusion genes such as AML1-ETO (22, 23),
a fusion protein resulting from t(8,21) translocation that com-
monly occurs in AML. Another typical example is the fact that
Bcr-Abl is a constitutively active, cytoplasmic tyrosine kinase
that is generated by t(9;22) translocation in more than 95%
of CML (24).
The central role of epigenetic modification of these genes
in leukemia development promoted them as reasonable tar-
gets for understanding the differential mechanism between
acute and chronic leukemia. In the present study, ID4, SFRP1,
and SHIP1 were hypermethylated in AML compared to CML.
These results suggest that the epigenetic modification of these
genes may play specific roles in the development of AML rather
than CML and, thus, promoted them as ideal targets for drug
development to treat AML. In the future, it is clearly imper-
ative to understand the patho-physiological differential mech-
anisms of these genes in AML, and to finally explore novel
therapeutic strategies.
In present study, methylation frequencies of SHP1 gene
were the high detected in CML as well as AML. SHP1 is a
member of the SHP family of proteins, cytoplasmic protein
tyrosine phosphatase (PTP), and has been known as a candi-
date tumor suppressor gene in lymphoma, leukemia and other
cancers (25). Also, the hypermethylation of SHP1 gene was
frequently detected in several human cancers and the reduced
expression of the SHP1 gene in various types of leukemias
and lymphomas mainly occurred by promoter methylation
(26-28). Therefore, these results indicate that aberrant DNA
methylation of SHP1 gene may be related to the tumorigenic-
ity of myeloid leukemia.
The methylation frequencies of the DAB2IP, DLC-1, and
RUNX3 genes were detected at different levels in acute and
chronic leukemia patients; however, the difference was neg-
ligible. In some genes like Integrin α 4gene, the promoter me-
thylation was not observed in most of the cases. However, hy-
permethylation of these genes was frequent event in esopha-
geal squamous cell carcinomas, lung cancers, and gastric can-
cers (11, 12, 15, 16). Thus, DNA methylation of these genes
may be not related to tumorigenicity of AML/CML in con-
trast with other cancers.
In summary, we have identified that aberrant DNA methy-
lation of SHP1 is a frequent event in AML and CML. Also,
the frequencies of DNA methylation of several methylation-
controlled genes, including ID4, SFRP1, and SHP1, were
higher in AML patients compared to those in CML patients.
Although these results should be confirmed, more compre-
hensive studies are necessary involving various known risk
factors such as smoking and occupational carcinogens, and
genetic susceptibilities. Our results suggest that aberrant DNA
methylation of SHP1 may be related to the tumorigenicity
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*P<0.05.
N, normal peripheral bloods; A, acute myeloid leukemia; C, chronic myeloid leukemia.
DAB2IP DLC-1 H-cadherin ID4 Integrin alpha 4 Runx3 SFRP1 SHP1
N 0/22 (0%) 0/22 (0%) 5/22 (22.7%) 3/22 (13.6%) 0/22 (0%) 0/22 (0%) 0/22 (0%) 0/22 (0%)
A 1/23 (4.3%) 2/23 (8.7%) 6/23 (26.1%) 15/23 (65.2%)* 0/23 (0%) 1/23 (4.3%) 15/23 (65.2%)* 18/23 (78.3%)*
C 0/21 (0%) 0/21 (0%) 4/21 (19.0%) 3/21 (14.3%) 0/21 (0%) 0/21 (0%) 2/21 (9.5%) 6/21 (28.6%)
Table 2. Methylation frequencies in normal peripheral bloods, acute myeloid leukemias, and chromic myeloid leukemiasof AML and CML and hypermethylation of ID4, SFRP1, and
SHP1 genes may contribute to the pathogenesis mechanism
of AML specifically.
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